Giles Richard Platford, President of Takeda Pharmaceutical Co. Ltd.'s International Business Unit, filed a Form 144 notice on October 30, 2026, proposing the sale of 55,617 American Depositary Shares of Takeda Pharmaceutical Co. Ltd. on or around November 1, 2026.

Key Highlights

  • Proposed sale: 55,617 American Depositary Shares (ADSs) with an aggregate market value of $1,121,794.89, according to the filing.
  • Source of shares: The ADSs were acquired on July 30, 2024, through Restricted Stock Unit Awards that vested on that date, with compensation listed as the nature of payment.
  • Shares outstanding: The filing lists 198,318,946 shares or other units outstanding at the time of the notice.
  • Prior sale disclosed: Platford sold 31,083 ADSs on August 10, 2026, for gross proceeds of $531,519.30, which the filing states was "conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026."
  • Broker named: Interactive Brokers LLC, One Pickwick Plaza, Greenwich, CT 06830, is identified as the broker for the proposed sale.
  • Exchange: The ADSs are listed on NYSE; the issuer is Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), SEC File Number 001-38757.

Platford's Proposed ADS Sale and Prior Three-Month Transactions

According to the Form 144 filing dated October 30, 2026, Giles Richard Platford, in his capacity as President of Takeda Pharmaceutical Co. Ltd.'s International Business Unit, is proposing to sell 55,617 ADSs with an approximate sale date of November 1, 2026. The filing was signed by Kate Huleatt, by power of attorney for Giles R. Platford. The aggregate market value of the proposed sale is reported as $1,121,794.89.

The securities proposed for sale were acquired on July 30, 2024, through Restricted Stock Unit Awards that vested on that date. The filing identifies Takeda Pharmaceutical Company Limited as the entity from whom the shares were acquired and describes the nature of payment as compensation. No cash purchase price was involved in the acquisition.

In the section covering securities sold during the past three months, the filing discloses that Platford sold 31,083 ADSs on August 10, 2026, generating gross proceeds of $531,519.30. The filing's remarks section states that this prior sale "was conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026." The filer's CIK is listed as 0001977620, and the issuer's address is 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan.

What Was Disclosed

A Form 144 notice was filed on October 30, 2026, by Giles Richard Platford of Takeda Pharmaceutical Co. Ltd., disclosing a proposed sale of 55,617 ADSs valued at $1,121,794.89, with shares sourced from vested Restricted Stock Unit Awards acquired July 30, 2024.